BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) told investors it has now finalized and executed the previously announced US distribution agreement struck with private Spanish pharma group Procare Health to market Papilocare and Oral Immunocaps.
Developed by Procare Health, Papilocare is the world’s first and only patented vaginal gel product with clinical evidence to prevent and treat HPV-dependent cervical lesions.
Immunocaps, which…